For the year ending 2025-12-31, DXCM had $311,800K increase in cash & cash equivalents over the period. $1,077,200K in free cash flow.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net income | 836,300 | 576,200 | 541,500 | 341,200 |
| Depreciation and amortization | 251,800 | 217,700 | 186,000 | 155,900 |
| Share-based compensation | 159,600 | 170,400 | 150,800 | 126,500 |
| Collaborative research and development fee | - | - | 0 | 0 |
| Loss on extinguishment of debt | - | - | 0 | 0 |
| Non-cash interest expense | 7,300 | 7,500 | 7,800 | 6,300 |
| Realized (gain) loss on equity investment | - | - | 1,900 | 200 |
| Deferred income taxes | 182,200 | -43,800 | -55,000 | -21,600 |
| Net (gains) losses on equity investments | 78,100 | - | - | - |
| Other non-cash income and expenses | 21,800 | 47,300 | 83,900 | -34,700 |
| Accounts receivable, net | 201,900 | 35,000 | 260,100 | 199,900 |
| Inventory | 63,700 | -12,400 | 252,600 | -49,300 |
| Prepaid and other assets | 14,800 | 5,800 | -19,300 | 131,600 |
| Operating lease right-of-use assets and liabilities, net | 7,100 | 6,500 | 4,500 | 5,800 |
| Accounts payable and accrued liabilities | 347,000 | 211,700 | 466,500 | 295,100 |
| Accrued payroll and related expenses | 55,400 | -60,000 | 37,200 | 8,500 |
| Deferred revenue and other liabilities | -11,500 | -8,000 | -2,600 | 11,100 |
| Net cash provided by operating activities | 1,440,700 | 989,500 | 748,500 | 669,500 |
| Purchases of marketable securities | 1,246,600 | 2,576,300 | 3,200,400 | 2,266,300 |
| Proceeds from sale and maturity of marketable securities | 2,164,700 | 2,824,400 | 2,947,400 | 2,127,800 |
| Purchases of property and equipment | 363,500 | 358,800 | 236,600 | 364,800 |
| Acquisitions, net of cash acquired | - | 0 | 0 | 3,900 |
| Purchases of non-marketable equity securities | 19,200 | 81,300 | - | - |
| Other investing activities | -600 | 15,500 | 17,600 | 14,300 |
| Net cash provided by (used in) investing activities | 536,000 | -207,500 | -507,200 | -521,500 |
| Net proceeds from issuance of common stock | 28,100 | 28,200 | 26,600 | 22,500 |
| Purchases of treasury stock | 500,000 | 750,000 | 688,700 | 557,700 |
| Proceeds from issuance of convertible notes, net of issuance costs | 0 | 0 | 1,230,600 | 0 |
| Purchases of capped call transactions | 0 | 0 | 101,300 | - |
| Payments for conversions of senior convertible notes | 0 | 0 | 787,300 | - |
| Repurchase of convertible notes | - | - | - | 0 |
| Repayments for maturity of senior convertible notes | 1,207,500 | - | - | - |
| Other financing activities | -7,000 | -13,000 | 1,500 | -17,300 |
| Net cash used in financing activities | -1,686,400 | -734,800 | -318,600 | -552,500 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 21,500 | -7,400 | 1,500 | -5,800 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 311,800 | 39,800 | -75,800 | -410,300 |
| Cash and cash equivalents at beginning of period | 607,300 | 567,500 | 643,300 | 1,053,600 |
| Cash and cash equivalents at end of period | 919,100 | 607,300 | 567,500 | 643,300 |
DEXCOM INC (DXCM)
DEXCOM INC (DXCM)